FI20002127A0 - Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi - Google Patents

Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Info

Publication number
FI20002127A0
FI20002127A0 FI20002127A FI20002127A FI20002127A0 FI 20002127 A0 FI20002127 A0 FI 20002127A0 FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A0 FI20002127 A0 FI 20002127A0
Authority
FI
Finland
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Application number
FI20002127A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Kim Pettersson
Timo Loevgren
Hans Lilja
Pauliina Nurmikko
Original Assignee
Artic Partners Oy Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artic Partners Oy Ab filed Critical Artic Partners Oy Ab
Priority to FI20002127A priority Critical patent/FI20002127A0/fi
Publication of FI20002127A0 publication Critical patent/FI20002127A0/fi
Priority to DE60137949T priority patent/DE60137949D1/de
Priority to AU2001291911A priority patent/AU2001291911A1/en
Priority to AT01972118T priority patent/ATE425460T1/de
Priority to US10/381,132 priority patent/US7872104B2/en
Priority to ES01972118T priority patent/ES2322432T3/es
Priority to EP01972118A priority patent/EP1320756B1/fr
Priority to PCT/FI2001/000834 priority patent/WO2002027323A1/fr
Priority to JP2002530851A priority patent/JP5254517B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI20002127A 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi FI20002127A0 (fi)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
DE60137949T DE60137949D1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
AU2001291911A AU2001291911A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
AT01972118T ATE425460T1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
US10/381,132 US7872104B2 (en) 2000-09-27 2001-09-26 Antibody, immunoassay and method for prostate cancer detection
ES01972118T ES2322432T3 (es) 2000-09-27 2001-09-26 Nuevo anticuerpo, inmunoensayo y procedimiento para la deteccion del cancer de protasta.
EP01972118A EP1320756B1 (fr) 2000-09-27 2001-09-26 Nouvel anticorps, dosage immunologique et methode de detection du cancer de la prostate
PCT/FI2001/000834 WO2002027323A1 (fr) 2000-09-27 2001-09-26 Nouvel anticorps, dosage immunologique et methode de detection du cancer de la prostate
JP2002530851A JP5254517B2 (ja) 2000-09-27 2001-09-26 新規抗体、イムノアッセイおよび前立腺癌検出方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Publications (1)

Publication Number Publication Date
FI20002127A0 true FI20002127A0 (fi) 2000-09-27

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Country Status (9)

Country Link
US (1) US7872104B2 (fr)
EP (1) EP1320756B1 (fr)
JP (1) JP5254517B2 (fr)
AT (1) ATE425460T1 (fr)
AU (1) AU2001291911A1 (fr)
DE (1) DE60137949D1 (fr)
ES (1) ES2322432T3 (fr)
FI (1) FI20002127A0 (fr)
WO (1) WO2002027323A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754812B (zh) 2007-05-04 2013-06-26 克拉洛诊断仪器公司 流体连接器和微流体系统
EP3278877B1 (fr) 2009-02-02 2020-06-03 Opko Diagnostics, LLC Structures de commande d'une interaction de lumière au moyen de dispositifs microfluidiques
EP2771688B1 (fr) * 2011-10-25 2018-09-26 Memorial Sloan-Kettering Cancer Center Anticorps anti-psa libres en tant que produits de diagnostic, de pronostic et thérapeutiques pour le cancer de la prostate
CA2853669C (fr) 2011-10-28 2019-03-12 Fredax Ab Agents therapeutiques et utilisations de ceux-ci
CA2866007C (fr) 2012-03-05 2023-01-03 Oy Arctic Partners Ab Procedes et appareils utilises pour predire le risque de cancer de la prostate et d'hypertrophie de la prostate
WO2013146997A1 (fr) * 2012-03-30 2013-10-03 国立大学法人京都大学 Biomarqueur urinaire destiné à être utilisé dans un test pour le cancer de la prostate
PL3071595T3 (pl) 2013-11-19 2019-09-30 Fredax Ab Humanizowane przeciwciało przeciw kalikreinie-2
DE202015009668U1 (de) 2014-03-28 2019-01-21 Opko Diagnostics, Llc Zusammensetzungen zur Diagnose von Prostatakrebs
EP3253800B1 (fr) * 2015-03-27 2021-03-03 Opko Diagnostics, LLC Standards d'antigènes prostatiques et utilisations
ES2880682T3 (es) * 2015-10-05 2021-11-25 Fredax Ab Anticuerpos anti PSA (5A10) humanizados
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (fr) * 1993-07-22 1995-01-25 Wallac Oy Anticorps monoclonales contre les épitopes trouvés dans l'antigène spécifique de la prostate à l'état libre mais pas à l'état complexé avec l'alpha-1-antichymotrypsine
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
JP5284554B2 (ja) 1997-04-30 2013-09-11 ハイブリテック インコーポレイテッド 前立腺特異的抗原の形態およびその検出方法
US6482599B1 (en) 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection

Also Published As

Publication number Publication date
US7872104B2 (en) 2011-01-18
EP1320756A1 (fr) 2003-06-25
JP5254517B2 (ja) 2013-08-07
ATE425460T1 (de) 2009-03-15
EP1320756B1 (fr) 2009-03-11
JP2004509934A (ja) 2004-04-02
AU2001291911A1 (en) 2002-04-08
US20040101914A1 (en) 2004-05-27
WO2002027323A1 (fr) 2002-04-04
ES2322432T3 (es) 2009-06-22
DE60137949D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Mikolajczyk et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
Fritzsche et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
Cho et al. High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma
FI20002127A0 (fi) Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
Shariat et al. New blood‐based biomarkers for the diagnosis, staging and prognosis of prostate cancer
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
EA023466B1 (ru) Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
TR200001253T2 (tr) Tümöre özel antijenler
Zargaran et al. Immunohistochemical evaluation of type IV collagen and laminin‐332 γ2 chain expression in well‐differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut‐off
ATE350662T1 (de) Markerproteine für prostatakrebs
ATE283483T1 (de) Tumorenspezifisches p450 protein
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
Oh et al. Comparisons of remnant primary, residual, and recurrent gastric cancer and applicability of the 8th AJCC TNM classification for remnant gastric cancer staging
Björk et al. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
Chhieng et al. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma
AU4623599A (en) Method for diagnosing an adenocarcinoma or a benign prostate pathology
Haese et al. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
EP1539818A4 (fr) Compositions permettant d'identifier et de cibles des cellules cancereuses exprimant une provasopressine et utilisations
Bussemakers Changes in gene expression and targets for therapy
EP1572225A4 (fr) Fragments de thrombospondine et utilisations dans des essais cliniques sur le cancer et production d'anticorps et autres agents de liaison